Abstract Library

#4243 Role of gastric mucosa evaluation in diagnostic of pancreatic neuroendocrine tumors functional status

Introduction: Accessibility of high-precision imaging dramatically increased detection rate of small asymptomatic pancreatic neuroendocrine tumors (PanNETs). Functioning status is indication for surgical treatment with high perioperative risks, while increased level of NET markers could be associated with gastric mucosa atrophy or intake of proton pump inhibitors (PPI) and nor with tumor secretion.

Conference:

Presenting Author:

Authors: Salimgereeva D, Feidorov I, Konyakhina A,

Keywords: PanNET, chronic atrophic gastritis, marker, OLGA, anti-parietal cell antibodies,

#3152 Vasostatin-1 as pancreatic neuroendocrine tumor (PanNET) biomarker: A comparison between preoperative and postoperative measurements

Introduction: No reliable biomarkers are currently available for pancreatic neuroendocrine tumors (PanNET). Vasostatin-1 (VS-1), the N-terminal fragment of Chromogranin A (CgA), seems to be more reliable than CgA as its plasma levels are not altered by proton pump inhibitors. An association between preoperative VS-1 and pathological features of aggressiveness was previously reported in a cohort of patients with resected nonfunctioning (NF)-PanNET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Manzoni M, Colombo B, Muffatti F,

Keywords: pancreatic neuroendocrine tumor, biomarker, chromogranin A, vasostatin-1,

#2691 Somatostatin Analogs in Patients with Zollinger Ellison Syndrome (ZES): An Observational Study

Introduction: Zollinger Ellison syndrome (ZES) is a rare syndrome caused by gastrin hypersecretion from a primary neuroendocrine tumor (NET), usually located within the duodenum or into the pancreas. Gastrinomas have two important treatment goal: the control of the gastrin-excess state and the control of tumor growth.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: massironi s

Authors: Massironi S, Peracchi M, Elvevi A, Cristoferi L, Quatrini M,

Keywords: ZES, gastrinoma, somatostatin analogs,

#1756 Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety

Introduction: Zollinger-Ellison syndrome (ZES) can cause severe complications. In multiple endocrine neoplasia type 1 (MEN1) related ZES, surgery has a controversial role and proton pump inhibitors (PPI) are usually first-line therapy, although some concerns regarding long-term use. Somatostatin analogs (SSA) both reduce hypergastrinemia and have an antiproliferative role.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: somatostatin analogs, MEN1, Zollinger-Ellison syndrome,

#1069 Gastric Neuroendocrine Neoplasms and Long-Term Proton Pump Inhibitors: Need for a Revision of Classifications?

Introduction: Gastric neuroendocrine neoplasm (gNENs) include three types: type 1 and 2 related to hypergastrinemia due to chronic atrophic gastritis(CAG) or Zollinger-Ellison syndrome (ZES) respectively, and type 3 normogastrinemic and more aggressive. Few cases of gNENs in patients taking proton pump inhibitors (PPI) have been reported

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Cavalcoli f

Authors: Cavalcoli F, Zilli A, Conte D, Ciafardini C, Massironi S,

Keywords: PPI, gNEN, classification, CAG,